Open Access

S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats

  • Authors:
    • Yichen Guo
    • Lianqun Cui
    • Shiliang Jiang
    • Dongmei Wang
    • Shu Jiang
    • Chen Xie
    • Yanping Jia
  • View Affiliations

  • Published online on: June 23, 2016     https://doi.org/10.3892/mmr.2016.5440
  • Pages: 1538-1552
  • Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

S100 Ca2+-binding protein A1 (S100A1) is an important regulator of myocardial contractility. The aim of the present study was to identify the underlying mechanisms of S100A1 activity via profiling the protein expression in rats administered with an S100A1 adenovirus (Ad‑S100A1‑EGFP) following acute myocardial infarction (AMI). LTQ OrbiTrap mass spectrometry was used to profile the protein expression in the Ad‑S100A1‑EGFP and control groups post‑AMI. Using Protein Analysis Through Evolutionary Relationships (PANTHER) analysis, 134 energy metabolism‑associated proteins, which comprised 20 carbohydrate metabolism‑associated and 27 lipid metabolism associated proteins, were identified as differentially expressed in the Ad‑S100A1‑EGFP hearts compared with controls. The majority of the differentially expressed proteins identified were important enzymes involved in energy metabolism. The present study identified 12 Ca2+‑binding proteins and 22 cytoskeletal proteins. The majority of the proteins expressed in the Ad‑S100A1‑EGFP group were upregulated compared with the control group. These results were further validated using western blot analysis. Following AMI, Ca2+ is crucial for the recovery of myocardial function in S100A1 transgenic rats as indicated by the upregulation of proteins associated with energy metabolism and Ca2+‑binding. Thus, the current study ascertained that energy production and contractile ability were enhanced after AMI in the ventricular myocardium of the Ad‑S100A1‑EGFP group.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 14 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo Y, Cui L, Jiang S, Wang D, Jiang S, Xie C and Jia Y: S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats. Mol Med Rep 14: 1538-1552, 2016
APA
Guo, Y., Cui, L., Jiang, S., Wang, D., Jiang, S., Xie, C., & Jia, Y. (2016). S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats. Molecular Medicine Reports, 14, 1538-1552. https://doi.org/10.3892/mmr.2016.5440
MLA
Guo, Y., Cui, L., Jiang, S., Wang, D., Jiang, S., Xie, C., Jia, Y."S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats". Molecular Medicine Reports 14.2 (2016): 1538-1552.
Chicago
Guo, Y., Cui, L., Jiang, S., Wang, D., Jiang, S., Xie, C., Jia, Y."S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats". Molecular Medicine Reports 14, no. 2 (2016): 1538-1552. https://doi.org/10.3892/mmr.2016.5440